NCT05860595
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 4 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Aug 20, 2025 to Aug 20, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 42 words
- Study completion pushed from Oct 24, 2025 to Oct 24, 2028
- Secondary endpoints: details revised at 1 of 3 entries
- Collaborators: details revised at 1 of 1 entry
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 20, 2023 to May 23, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of participants with successful lentiviral vector transduced CD34+ stem cell engraftment
Timeframe: Up to 42 days post transplant
Engraftment time of neutrophil
Timeframe: Up to 42 days post transplant
Engraftment time of platelet
Timeframe: Up to 42 days post transplant
Transplant-related mortality within 100 days and within 1 year after reinfusion of KL003 drug product
Timeframe: Up to 1 year post transplant
The number, frequency and severity of adverse events (AE) within 1 year after reinfusion of KL003 drug products
Timeframe: Up to 24 months post transplant
Secondary (3)
The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months
The duration of transfusion independence
Changes in the frequency and volume of blood transfusion
Arms and interventions
KL003 cell injection Drug ProductExperimental
Each recruited subject will accept KL003 Transplantation.
Genetic: KL003 cell injection Drug Product
Sites
1 site in 1 country
- Regenerative Medicine CenterTianjin, Tianjin Municipality, China